BioNTech SE will report second-quarter results before the bell Tuesday, with investors bracing for widening losses as the German biotech company navigates a steep decline in COVID-19 vaccine revenue while betting on its emerging oncology pipeline.
stock
Be The Investor Research
Read Original Source (Investing)
BioNTech earnings on deck as losses widen amid COVID decline
BioNTech SE will report second-quarter results before the bell Tuesday, with investors bracing for widening losses as the German biotech company navigates a steep decline in COVID-19 vaccine revenue while betting on its emerging oncology pipeline.